Letter to the Editor: Is There a Role for Switching Infliximab in Order to Regain Anti-TNF Response in Cases With Active Inflammatory Bowel Disease?

Letter to the Editor: Is There a Role for Switching Infliximab in Order to Regain Anti-TNF Response in Cases With Active Inflammatory Bowel Disease? Inflamm Bowel Dis. 2019 Jul 13;: Authors: Mantaka A, Orfanoudaki E, Koutroubakis IE PMID: 31300823 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31300823?dopt=Abstract

Read More

No increased risk of nephrotoxicity associated with 5-aminosalicylic acid in IBD: a population-based cohort and nested case-control study.

No increased risk of nephrotoxicity associated with 5-aminosalicylic acid in IBD: a population-based cohort and nested case-control study. Aliment Pharmacol Ther. 2019 Jul 12;: Authors: Jairath V, Hokkanen SRK, Guizzetti L, Boxall N, Campbell-Hill S, Patel H Abstract BACKGROUND: There is conflicting evidence about nephrotoxicity risk associated with 5-aminosalicylates for treatment of IBD. AIMS: To determine population-based temporal trends for 5-aminosalicylates and estimated risk of nephrotoxicity associated with 5-aminosalicylate use for ulcerative colitis (UC) and Crohn’s disease (CD). METHODS: Retrospective cohort and nested case-control study, using the Health Improvement Network…

Read More

Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics.

Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics. Dig Dis Sci. 2019 Jul 09;: Authors: Chang JY, Cheon JH Abstract Thiopurines have been widely used for the maintenance of remission or steroid sparing in patients with inflammatory bowel disease. However, potential drug-related adverse events frequently interfere with their use. Indeed, drug withdrawals associated with adverse reactions have been reported in approximately 25% of patients. To balance the efficacy, safety, and tolerability of thiopurines, regular monitoring of biomarkers (complete blood cell count, liver function test,…

Read More

Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.

Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial. Gut. 2019 Jul 08;: Authors: Panaccione R, Colombel JF, Travis SPL, Bossuyt P, Baert F, Vaňásek T, Danalıoğlu A, Novacek G, Armuzzi A, Reinisch W, Johnson S, Buessing M, Neimark E, Petersson J, Lee WJ, D’Haens GR Abstract OBJECTIVE: To evaluate the cost-effectiveness of an inflammatory biomarker and clinical symptom directed tight control strategy (TC) compared with symptom-based clinical management (CM) in patients with Crohn’s disease (CD) naïve to immunosuppressants and biologics using…

Read More

Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease.

Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 Jul 09;: Authors: Bauman LE, Xiong Y, Mizuno T, Minar P, Fukuda T, Dong M, Rosen MJ, Vinks AA Abstract BACKGROUND: Many pediatric patients with inflammatory bowel disease (IBD) lose response to infliximab (IFX) within the first year, and achieving a minimal target IFX trough concentration is associated with higher remission rates and longer durability. Population pharmacokinetic (PK) modeling can predict trough concentrations for individualized dosing. THE OBJECT OF THIS STUDY WAS…

Read More

Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn’s disease.

Related Articles Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn’s disease. Gastroenterology. 2019 Jul 04;: Authors: Danese S, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, Siegelman J, Jones S, Bornstein J, Feagan BG Abstract BACKGROUND & AIMS: Vedolizumab is a gut-selective monoclonal antibody for the treatment of moderately to severely active Crohn’s disease (CD). We performed a prospective study of endoscopic, radiologic, and histologic healing in patients with CD who received vedolizumab therapy. METHODS: We performed a phase 3b, open-label, single-group study of…

Read More

Response to: Value of VAV3 methylation in stool DNA might be restricted to non-thiopurine treated inflammatory bowel disease patients (CGH-D-19-01071).

Related Articles Response to: Value of VAV3 methylation in stool DNA might be restricted to non-thiopurine treated inflammatory bowel disease patients (CGH-D-19-01071). Clin Gastroenterol Hepatol. 2019 Jul 04;: Authors: Kisiel JB, Mahoney DW, Taylor WR, Klepp P PMID: 31279948 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31279948?dopt=Abstract

Read More

Antibiotic Use in Childhood and Adolescence and Risk of Inflammatory Bowel Disease: A Case-Control Study in the UK Clinical Practice Research Datalink.

Antibiotic Use in Childhood and Adolescence and Risk of Inflammatory Bowel Disease: A Case-Control Study in the UK Clinical Practice Research Datalink. Inflamm Bowel Dis. 2019 Jul 02;: Authors: Troelsen FS, Jick S Abstract BACKGROUND: Inflammatory bowel disease (IBD) causes serious morbidity and disability, and the incidence is increasing. The disease etiology is not well understood, though inflammatory reactions after antibiotic exposure may be associated with development of IBD. We investigated the association between IBD and prior antibiotic use. METHODS: We conducted this case-control study among individuals in the United…

Read More

Gender Differences and Other Factors Associated with Weight Gain Following Initiation of Infliximab: A Post Hoc Analysis of Clinical Trials.

Gender Differences and Other Factors Associated with Weight Gain Following Initiation of Infliximab: A Post Hoc Analysis of Clinical Trials. Inflamm Bowel Dis. 2019 Jul 02;: Authors: Christian KE, Russman KM, Rajan DP, Barr EA, Cross RK Abstract BACKGROUND: In our clinical practice, women often report excess weight gain with infliximab (IFX) use. There are currently no studies investigating weight gain after antitumor necrosis factor therapy in patients with inflammatory bowel disease. The objective of this study was to evaluate the association of clinical factors, with a particular focus on…

Read More
<< Go Back